美股异动丨诺和诺德夜盘大涨近10%，Wegovy口服片美国获批

Core Viewpoint - Danish pharmaceutical giant Novo Nordisk (NVO.US) saw a nearly 10% increase in after-hours trading, reaching $52.79, following the FDA's approval of Wegovy (semaglutide) tablets for oral GLP-1 use in weight management [1] Group 1: Product Approval - Wegovy oral tablets are the first oral GLP-1 receptor agonist approved for weight management [1] - The approval is based on the OASIS and SELECT trial programs [1] Group 2: Clinical Trial Results - In the OASIS 4 trial, a daily dose of 25 mg semaglutide resulted in an average weight loss of 16.6% [1] - The weight loss effect achieved with Wegovy oral tablets is similar to that of the injectable Wegovy at 2.4 mg [1] Group 3: Market Launch - Wegovy oral tablets are expected to be available in the U.S. by early January 2026 [1]